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ABSTRACT
Human noroviruses (HuNoV) are a significant cause of acute gastroenteritis in the developed world, and yet our understanding
of the molecular pathways involved in norovirus replication and pathogenesis has been limited by the inability to efficiently cul-
ture these viruses in the laboratory. Using the murine norovirus (MNV)model, we have recently identified a network of host
factors that interact with the 5= and 3= extremities of the norovirus RNA genome. In addition to a number of well-known cellular
RNA binding proteins, the molecular chaperone Hsp90 was identified as a component of the ribonucleoprotein complex. Here,
we show that the inhibition of Hsp90 activity negatively impacts norovirus replication in cell culture. Small-molecule-mediated
inhibition of Hsp90 activity using 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin) revealed that Hsp90
plays a pleiotropic role in the norovirus life cycle but that the stability of the viral capsid protein is integrally linked to Hsp90
activity. Furthermore, we demonstrate that both theMNV-1 and the HuNoV capsid proteins require Hsp90 activity for their
stability and that targeting Hsp90 in vivo can significantly reduce virus replication. In summary, we demonstrate that targeting
cellular proteostasis can inhibit norovirus replication, identifying a potential novel therapeutic target for the treatment of noro-
virus infections.
IMPORTANCE
HuNoV are a major cause of acute gastroenteritis around the world. RNA viruses, including noroviruses, rely heavily on host cell
proteins and pathways for all aspects of their life cycle. Here, we identify one such protein, the molecular chaperone Hsp90, as an
important factor required during the norovirus life cycle. We demonstrate that both murine and human noroviruses require the
activity of Hsp90 for the stability of their capsid proteins. Furthermore, we demonstrate that targeting Hsp90 activity in vivo
using small molecule inhibitors also reduces infectious virus production. Given the considerable interest in the development of
Hsp90 inhibitors for use in cancer therapeutics, we identify here a new target that could be explored for the development of anti-
viral strategies to control norovirus outbreaks and treat chronic norovirus infection in immunosuppressed patients.
Human noroviruses (HuNoV) are a major cause of viral epi-demic gastroenteritis and a significant cause ofmorbidity and
mortality worldwide (1–3). HuNoV are mainly transmitted
through the fecal-oral route (4). Although norovirus disease is
usually short-lived and self-limiting, immunocompromised pa-
tients can become chronically infected, with symptoms lasting for
weeks or years (5, 6). Despite significant efforts, HuNoV have yet
to be cultured efficiently in the laboratory. However, our under-
standing of their biology has improved significantly in recent years
(7, 8), and a recent study has demonstrated limited replication in
immortalized B cells in the presence of enteric bacteria (9). Some
of these advances have been due to the discovery of a murine
norovirus (MNV), which can be cultivated in cell culture (10).
Reverse-genetics approaches and small animal models for MNV
have enabled better insights into the norovirus life cycle, including
the identification of cellular factors and pathways involved in no-
rovirus replication (11–14).
As obligate intracellular parasites, viruses rely heavily on the
cellular pathways and processes for almost every step of their life
cycle. RNA viruses typically have small genomes and therefore
possess limited coding capacity. As a result, RNA viruses typically
utilize numerous mechanisms to increase the information con-
tainedwithin their genomes. Thesemechanisms include the use of
translational frameshifting and other novel translation mecha-
nisms, as well as the incorporation of large polyproteins, which are
processed to produce precursors, as well as the final mature pro-
tein products, each of which can have different functional prop-
erties (15, 16). In addition, the genomes of RNA viruses invariably
fold to form RNA structures that interact with both cellular and
viral proteins to regulate many aspects of the viral life cycle. These
types of interactions are known to contribute to genome replica-
tion, translation, encapsidation, and pathogenesis (17–23). For
example, a single nucleotide change in the poliovirus internal ri-
bosome entry site (IRES) structure leads to the attenuation of
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virus in a cell-specific manner (24, 25), whereas the deletion of a
polypyrimidine tract in theMNV3=-untranslated region (3=UTR)
leads to attenuation of virus in vivo (26). The identification and
inhibition of these viral RNA-host protein interactions have been
shown to have the potential to control viral infections (27, 28).
Targeting a host protein has the additional advantage of a high
genetic barrier to drug resistance due to the extremely low muta-
tional rate of eukaryotic cells. In contrast, RNA viruses encode
RNA-dependent RNA polymerases which lack proofreading ca-
pacity, leading to the generation of a mutant spectra referred to as
“quasispecies,” greatly facilitating the emergence of drug resis-
tance (29–31).
Using a riboproteomics-based approach, we recently identified
heat shock protein 90 (Hsp90) as one component of a network of
host proteins that interact directly or indirectly with the 5= and 3=
extremities of the MNV-1 genome (32). Given the multifunc-
tional nature of viral proteins, it is not surprising that Hsp90 ap-
pears to play a role in the life cycles of many pathogenic viruses
and that targeting Hsp90 can effectively control virus replication
in cell culture (33). In the present study, we have further investi-
gated the role of Hsp90 in the norovirus life cycle and, in addition
to our observed RNA binding activity of Hsp90, we identified that
the major capsid protein VP1 of both MNV-1 and HuNoV are
Hsp90 client proteins. Importantly, we further demonstrate that
inhibitingHsp90 negatively impacts norovirus replication both in
cell culture and in vivo. We provide here a proof of principle that
targeting a molecular chaperone may provide a therapeutic ap-
proach for treating or controlling norovirus infections.
MATERIALS AND METHODS
Cell culture and preparation of BMDMs. The murine microglial BV-2
and 293T cell lines were maintained in Dulbecco modified Eagle medium
(Gibco) supplemented with 10% fetal calf serum (Biosera), 2 mM L-glu-
tamine (Gibco), and antibiotics (100 U of penicillin/ml and 100 g of
streptomycin/ml). Baby hamster kidney cells expressing T7 DNA
polymerase (BSRT7 cells) were cultured inmedium described above con-
taining G418 at a concentration of 1 mg/ml. Primary bone marrow-de-
rived macrophages (BMDMs) were prepared from Atg5flox/flox and
Atg5flox/floxLysMcre mice as described previously (34).
Virus and reagents. The MNV-1 CW1 strain was used for all cell
culture experiments, whereas the CW3 strain was used for the infection of
mice. Neutral red (NR)-containing viral stocks were prepared in the ab-
sence of white light as described previously (35, 36). Antisera against viral
proteins were developed in the laboratory and were described previously
(32, 37). Antibodies against host factors were purchased from the follow-
ing suppliers: Akt (Santa Cruz, sc-8312), Hsp90 (Santa Cruz, sc-59578),
LC3B (Sigma, L7543), and beta-actin (Sigma, A5316).The inhibitors
17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)
and 17-allylamino-17-demethoxygeldanamycin (17-AAG) were pur-
chased from Selleckbio, lactacystin was purchased from Cayman Chemi-
cals, and novobiocin was purchased from Cambridge Biosciences. The
chemicals were used at the concentrations indicated in the text. His-
tagged recombinant Hsp90 was purchased from Cayman Chemicals,
whereas recombinantHis-tagged glutathione S-transferase (GST) protein
was provided by Stephen Graham, University of Cambridge. His-tagged
recombinant polypyrimidine-binding protein (PTB) and viral protein
NS7 were prepared as described previously (38, 39). The plasmids
pT7MNV:Rz, pSG, and pMNV-1 VP1 expressing MNV-1 genomic RNA,
subgenomic RNA, and VP1 genes, respectively, as well as the plasmid
pHuNOV VP1 expressing HuNoV VP1 gene, were cloned under T7 pro-
moter in either pTriex or pcDNA3.1 vectors. BSRT7 cells were infected
with fowlpox virus expressing T7 RNA polymerase before transfections as
described earlier (13). A plasmid expressing green fluorescent protein
(GFP)-Hsp90 was a gift from Edouard Bertrand and was described pre-
viously (40). Where noted, cells were transfected using Lipofectamine
2000 according to the manufacturer’s instructions (Life Technology).
Enrichment of RNA binding proteins using RNA affinity purifica-
tion. RNA affinity purifications were performed as described previously
(32). Briefly, RNA transcripts representing 5= and 3= extremities of
MNV-1 genome and a control RNA representing a portion of the ampi-
cillin resistance gene were prepared by in vitro transcription and cova-
lently coupled to cyanogen bromide-activated Sepharose. The RNA-
linked Sepharosewere then incubatedwith 7.5mgof BV-2 S-100 lysates in
the presence of 100 g of yeast RNA, 1 mM ATP, 1 mM GTP, and 100 U
of RNasin RNase inhibitor (Promega) at 4°C for 2 h with continuous
mixing. RNA-protein complexes were washed three times with binding
buffer at 4°C, and proteins were eluted by boiling in the presence reducing
SDS-PAGE loading buffer. The eluted proteins were analyzed byWestern
blot analysis.
Recombinant Hsp90 interaction with viral RNA. Ni-NTA resin (20
l of packed volume), pre-equilibrated withNT2 buffer (50mMTris [pH
7.4], 150 mM NaCl, 1 mM MgCl2, 0.05% Nonidet P-40), was incubated
with various His-tagged proteins in the presence of protease inhibitor at
4°C. After 2 h, resin was washed twice with ice-cold NT2 buffer and incu-
bated with 10 g of total RNA isolated fromMNV-1-infected cells in the
presence of 100 U of RNaseOUT and 10g of yeast RNA at 4°C. After 2 h,
the complexes were washed twice with ice-cold NT2 buffer, followed by
RNA extraction using a GenElute mammalian total RNA miniprep kit
(Sigma). RNA samples were analyzed by reverse transcription-quantita-
tive PCR (RT-qPCR) analysis according to a previously published proto-
col (41). For semiquantitative analysis, RT-PCR was performed as de-
scribed previously (32). Briefly, a 1/10 portion of the RNA was reverse
transcribed to cDNA using primer IGIC464 (CAAACATCTTTCCCTTG
TTC) targeting nucleotides (nt) 1779 to 1760 of the MNV-1 genome
utilizing M-MLV reverse transcriptase (Promega) according to the man-
ufacturer’s protocol. Then, 1/10 of the cDNA was subjected to PCR with
the primers IGIC200 (AACGCTCTGCTGGCCAGGATCAGC) targeting
nt 1416 to 1439 and primer IGIC464 to produce a 364-bp product encom-
passing nt 1416 to 1779 of the MNV-1 genome.
Detectionof viral RNAusing qRT-PCR.RNAwas reverse transcribed
to cDNA by using oligonucleotide IC464 (CAAACATCTTTCCCTTG
TTC) and AMV reverse transcriptase (Promega) as detailed in the man-
ufacturer’s instructions. cDNA was amplified by real-time PCR using
qPCR master mix (Eurogentec) on an ABI 7900 real-time PCR machine.
Briefly, cDNA was mixed with 2 buffer and the primers IC464 and
IC465 (TGGACAACGTGGTGAAGGAT), heat denatured to 95°C for 10
min, and subjected to 40 cycles of 94°C for 15 s, 58°C for 30 s, and 72°C for
30 s. The viral genome copy number was calculated by interpolation from
a standard curve generated using serial dilutions of standard RNA repre-
senting nt 1085 to 1986 of the MNV-1 genome.
Virus titer determination. Virus titers were quantified by plaque as-
say or a 50% tissue culture infective dose (TCID50) assay as described
earlier (42, 43).
IC50 and CC50 determination. The cytotoxicity of 17-DMAG for
BV-2 cells was determined by using a CellTiter-Blue cell viability assay
(Promega) according to the manufacturer’s guidelines. Briefly, BV-2 cells
were plated in quadruplicate at a density of 104 cells per well in a 96-well
plate in the presence of various concentrations of 17-DMAG. After 24 h of
incubation, 20 l of CellTiter-Blue reagent was added to the wells, the
incubation was continued for another 4 h, and the absorbance was mea-
sured at 570 and 600 nm. The final absorbance (A570–600) was calculated
by subtracting average culture medium absorbance at 600 nm from the
total absorbance values of experimental wells at 570 nm. A dose-response
curvewas plotted using theA570–600 values of untreated cells as 100%.The
50% cytotoxic concentration (CC50) was calculated from the dose-re-
sponse curve using nonlinear regression analysis. 17-DMAG displayed an
CC50 of 4.5M. In order to determine the potency of the inhibitory effect
of 17-DMAG on MNV-1, the 50% inhibitory concentration (IC50) in
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BV-2 cells was determined after 24 h of treatment. Briefly, the BV-2 cells
were infected with MNV-1 (multiplicity of infection [MOI], 5 TCID50/
cell) and incubated with various concentration of drugs 17-DMAG for 24
h. Samples were harvested for virus titer determinations using TCID50.
The dose-response curvewas plotted using the virus titer of untreated cells
as 100%, and the IC50 was calculated using nonlinear regression analysis.
17-DMAG displayed an IC50 of 0.06 M during single cycle MNV-1 rep-
lication in BV-2 cells. The selectivity index (SI; SI CC50/IC50) was cal-
culated to be 69.75.
Lumier assay.Murine and human Hsp90 genes were cloned by RT-
PCR from the total mRNAs isolated from the BV2 and HEK293T cell
lines, respectively. All MNV and HuNoV genes encoding individual pro-
teins were cloned fromMNV-1 and Norwalk strains, respectively. N-ter-
minalRenilla reniformis luciferase (RL) or S. aureus protein A (PA) fusion
protein plasmids were generated in pcDNA3-RL-GW and pTrex-
Dest30-PA expression vectors, respectively (a gift from Juergen Haas,
University of Edinburgh). Lumier assayswere performed in quadruplicate
as previously described using sheep anti-rabbit IgG-coated magnetic
beads (Invitrogen, Dynabeads M280) and a modified HENG lysis buffer
[20 mM HEPES (pH 7.8), 135 mM KCl, 2 mM MgCl2, 15 mM
(NH4)6Mo7O24, 0.5%NP-40, 0.1% bovine serum albumin, 1 mMATP, 1
mMdithiothreitol] with 1%Halt protease/phosphatase inhibitor cocktail
(ThermoScientific) andbenzonase (Novagen) (44).Negative andpositive
thresholds were determined by using a plasmid expressing the luciferase
fusion protein cotransfected with a plasmid construct expressing PA
alone. After 24 h of incubation, the cells were lysed on a shaker using 30l
of ice-cold lysis buffer for 10 min at 4°C. Protein expression was con-
firmed inHEK293T cells byWestern blotting. Lysateswere centrifuged for
15 min at 1,000 g at 4°C and transferred to a 96-well white flat-bottom
plate (Greiner) with beads, incubated for 1 h on a shaker at 4°C, and then
washed six times on a handheldmagnetic separator block fromMillipore.
After washing, the Renilla activity was measured on a GloMax luminom-
eter (Promega). Normalized Lumier intensity ratios (NLIR) and robust z
(rz) scores were calculated as previously described (45). An rz score above
3.72 (P 0.0001) was considered positive.
RNA interference reduction of Hsp90 levels. MNV-1 permissive
BV-2 cells were used for small interfering RNA (siRNA)-mediated protein
knockdown as described previously (32). Briefly, 6 106 BV-2 cells were
electroporated with 100 pmol of a pool of siRNAs against Hsp90/ (sc-
35610; Santa Cruz) at 1,700 V for 10 ms for three pulses using the Neon
transfection system (Invitrogen). The cells were plated in antibiotic-free
medium to allow recovery and incubated for 12 h. The cells were then
infected with MNV-1 (MOI, 0.01 TCID50/cell), and samples were har-
vested for RNA isolation, virus titer determinations, andWestern blotting
at various time points postinfection. The virus titer was determined by
determining the TCID50, and the viral RNA copy number was quantified
using RT-qPCR as described previously (32).
In vivo inhibition of MNV-1. All of the animal studies described here
were performed in accordance with local and federal guidelines as out-
lined in the Guide for the Care and Use of Laboratory Animals of the Na-
tional Institutes of Health. Protocols were approved by the University of
Michigan Committee on Use and Care of Animals (UCUCA
PRO00004534). 6- to 8-week-old BALB/c mice were purchased from
Jackson Laboratories and housed at the University of Michigan. Mice
were administered 30 mg/kg of 17-DMAG dissolved in 0.05% dimethyl
sulfoxide (DMSO) or vehicle control intraperitoneally 1 h prior to infec-
tion with light-sensitive, neutral red (NR) MNV-1 (106 PFU) by oral
gavage. The distal ileumwas harvested in the dark after 24 h, and the virus
titer was determined by plaque assay as previously described (35, 36).
RESULTS
Hsp90 interacts with the termini of the MNV-1 genome. The
termini of MNV genomes are highly conserved between strains
and fold into characteristic structures that we have shown to be
required for viral replication (Fig. 1A). We have previously iden-
tified Hsp90/ as a host factor that interacts with the 5= and 3=
termini of the MNV-1 genome using RNA affinity chromatogra-
phy and mass spectrometry (32). Many of the host proteins also
identified within the network of interacting proteins are known
Hsp90 client proteins (33). To independently corroborate the
binding of Hsp90 with the MNV-1 genome, we performed RNA
affinity chromatography as previously described (32), and the
presence of Hsp90 was verified by Western blot analysis of the
eluted fractions. Hsp90 was enriched following RNA affinity pu-
rification on the 5= as well as the 3= extremity of the MNV-1
genomic RNA (Fig. 1B). Hsp90 was not enriched on a control
RNA (N/R) or with beads alone. To determine whether Hsp90
associated with viral RNA, we examined the ability of recombi-
nantHis-taggedHsp90 (rHsp90) to enrichMNV-1 genomic RNA
from total cellular RNA isolated fromMNV-1-infected cells. Pos-
itive-sense viral RNA was selectively enriched by immobilized
rHsp90, as well as with His-tagged poly-PTB and the viral poly-
merase NS7 (Fig. 1C). In contrast, negative-sense viral RNA was
not enriched by rHsp90 (data not shown). This observation sug-
gests an interaction of Hsp90 with viral RNA and agrees with
previous observations describing viral RNA binding activity of
Hsp90 in bamboo mosaic virus (46).
MNV-1 growth is dependent on Hsp90 levels in cell culture
system. To determine whether Hsp90 was required for some as-
pect of the norovirus life cycle, we examined the effects of siRNA-
mediated reduction of intracellular Hsp90/ levels on MNV-1
replication. siRNA-mediated targeting of Hsp90 resulted in a
99% reduction in Hsp90 levels, although detectable levels of
Hsp90 remained (Fig. 2A). Cells transfected with Hsp90 siRNA
were then infected with MNV-1 and the levels of viral RNA, viral
proteins, and infectious virus produced were examined using RT-
qPCR, Western blot, and TCID50 assays, respectively. Viral RNA
polymerase (NS7) production was reduced by 50% (Fig. 2A),
whereas genomic RNA levels, as well as virus titers, were reduced
significantly (Fig. 2B and C). In addition, overexpression of
Hsp90 in 293T cells resulted in a statistically significant increase
(4-fold) in MNV-1 titers after transfection of purified VPg-
linked MNV-1 RNA (Fig. 2D). Taken together, these data con-
firmed a requirement for Hsp90 in some aspect of theMNV-1 life
cycle.
Hsp90 activity is required forMNV-1 replication. Smallmol-
ecule inhibitors have been widely used to study the function of
Hsp90, as well as its role in the life cycle of several viruses (17, 33,
47–49).We examined the effect of the water-soluble Hsp90 inhib-
itor 17-DMAG on MNV-1 replication in cell culture (Fig. 3). 17-
DMAG is a geldanamycin (GA) analogue that binds to the ATP-
binding site in the N-terminal region of Hsp90, inhibiting
chaperone activity. We examined the ability of 17-DMAG to in-
terfere withMNV-1 replication in a virus yield assay, wherein cells
were infected at a low MOI (0.01 TCID50/cell), and the effect on
infectious virus yield at 24 h postinfection was determined. Treat-
ment of cells with 0.3 M 17-DMAG reduced the levels of infec-
tious MNV-1 produced by 4 orders of magnitude without sig-
nificant cytotoxicity (Fig. 3A). Treatment with 17-AAG, another
analogue of GA, was also found to significantly reduce infectious
virus production using the same approach (data not shown).
To further confirm that the effect observed on MNV-1 repli-
cation is due to a direct inhibition ofHsp90 activity by 17-DMAG,
we also examined the effect of another unrelated inhibitor, novo-
biocin, on MNV-1 replication. Novobiocin is an aminocoumarin
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antibiotic, exhibiting potent activity against Gram-positive bacte-
ria and therefore structurally unrelated to 17-DMAG. In contrast
to 17-DMAG, which binds the N terminus of Hsp90, novobiocin
interacts with the C-terminal ATP binding site (50–52). Novobio-
cin treatment of cells also resulted in a significant decrease in
MNV-1 titers (Fig. 3B) without any overt signs of toxicity (data
not shown). These combined results suggested that the inhibition
of Hsp90 activity significantly reduces MNV-1 replication in cell
culture.
Due to high water solubility and favorable pharmacokinetic
properties, all further assays were performed with 17-DMAG. A
concentration of 0.3 M and a high MOI (5.0 TCID50/cell) was
used for all further experiments based on the concentration-effect
curve (Fig. 3C), since this concentration caused no toxicity while
being highly effective (2.5 log10) for the inhibition of MNV-1
replication.
Hsp90 activity is required for norovirus replication at a
postentry step. To rule out the possibility that 17-DMAG treat-
ment resulted in direct inactivation ofMNV-1 virions, the effect of
the inhibitor directly on virus viability was assayed. MNV-1 virus
stocks were incubated with 17-DMAG prior to extensive dilution
of the samples for titration. Pretreatment of MNV-1 with 17-
DMAG had no effect on the titers of the treated stocks, indicating
that 17-DMAG did not inactivate virions directly (Fig. 4A). To
examine a role for Hsp90 inMNV-1 entry or uncoating, the effect
of 17-DMAGon virus replication after transfection of VPg-linked
viral RNA into HEK293T cells was examined. Importantly, since
human cells are not susceptible toMNV-1 infection due to lack of
a suitable receptor (13), infectious titers from human cells repre-
sent a single cycle only. Inhibition of Hsp90 activity in HEK293T
cells by 17-DMAG resulted in a 3-log10 reduction in virus titer
(Fig. 4B). A similar reduction in titer was observed duringMNV-1
recovery from an infectious cDNA clone in BHK cells in the pres-
ence of 17-DMAG (data not shown). These data indicated that
Hsp90 activity functions at a postentry stage of the MNV-1 life
cycle.
FIG 1 Hsp90 interacts with the MNV-1 genomic RNA. (A) Murine norovirus genome organization and the encoded proteins are presented. The secondary
structure of 5= (5=G) and 3= extremities (3=Ex) with which Hsp90 interacts has been presented as a folded structure. (B) Hsp90 is enriched on the RNA affinity
columns representing the 5= and 3= extremities of the MNV-1 genome. RNA affinity columns representing 5=G, 3=Ex, and a control RNA (N/R), as well as beads
alone, were used to purify the host factors from BV-2 cells. The enriched proteins were examined by Western blot analysis to detect enrichment of Hsp90 and
GAPDH (glyceraldehyde-3-phosphate dehydrogenase). (C) Recombinant Hsp90 interacts specifically with the MNV-1 genome. His-tagged recombinant
proteins (Hsp90,GST, PTB, andNS7) coupled toNi-NTAbeadswere tested for its ability to bindpositive-strandMNV-1 genome. The bound viral RNAenriched
on these proteins was quantified by using RT-qPCR and expressed relative to bead controls. Bound viral RNAwas also amplified by using endpoint RT-PCR and
detected on an agarose gel. The experiment was performed in triplicate, and the error bars represent standard deviations.
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In order to further delineate the role of Hsp90 in the MNV-1
life cycle, we examined the effect of 17-DMAG addition at various
times postinfection (0, 6, and 9 h). Virus infections were per-
formed using a high MOI to ensure a single cycle of synchronous
replication. We observed that inhibition of Hsp90 activity had
maximal effect onMNV-1 titer when 17-DMAGwas added either
at 0 or 6 h postinfection. However, a small, yet statistically signif-
icant reduction in infectious virus production could be observed
even when 17-DMAG was added at 9 h postinfection (Fig. 4C).
These data again suggested that Hsp90 activity was required at a
postentry stage of the MNV-1 life cycle. To control for any non-
specific effects of Hsp90 inhibition on the MNV-1 replication, we
examined the levels of cellular proteins that have previously been
identified as being involved in the norovirus life cycle (Fig. 4D).
Inhibition of Hsp90 activity did not affect the levels of any of the
cellular proteins examined.
Inhibition of Hsp90 activity leads to the inability of MNV-1
genome to be encapsidated.Todefine the precise role ofHsp90 in
the norovirus life cycle, the effect of 17-DMAG was examined
using a high-multiplicity single-step growth curve. As expected
from our previous observations, Hsp90 activity inhibition using
0.3 M 17-DMAG resulted in decreased virus titer by up to 	3
log10 (Fig. 5A). In contrast, viral RNA levels were decreased only at
the later stages of infection and by up to	1 log10 only (Fig. 5B).
These observations suggested that although Hsp90 activity con-
tributes to viral RNA replication, the primary function of Hsp90
appears to be at a late stage of the viral life cycle, after viral RNA
synthesis has occurred. Hsp90 is a molecular chaperone, and its
activity is known to be required for the correct folding of a diverse
number of viral proteins. Inhibition of Hsp90 activity typically
leads to the specific degradation of these viral proteins (33, 53, 54).
We therefore examined the effect of 17-DMAG on the levels of
MNV-1 structural and nonstructural proteins during infection
(Fig. 5C) under the same conditions where cellular protein levels
were unaffected (see Fig. 4D). The structural proteins VP1 and
VP2 were almost undetectable in the presence of 17-DMAG at 12
h postinfection. As expected, due to the decrease in viral RNA
levels, a minor decrease in nonstructural protein levels was also
observed, although it is worth noting that not all proteins ap-
FIG 2 Hsp90 activity is required for MNV-1 replication. BV-2 cells were
transfected with either nonspecific (NSP) siRNA duplexes or siRNA targeting
Hsp90 and infected with MNV-1 at an MOI of 0.05 TCID50 per cell. Samples
were harvested at 24 h postinfection for analysis. (A) The levels of protein in
each sample were analyzed byWestern blot and quantified by using densitom-
etry. Samples were normalized to the level of GAPDH.Hsp90 andNS7 protein
levels in Hsp90 siRNA transfected cells are expressed relative to the levels in
NSP siRNA transfected cells. (B) Total infectious virus production was deter-
mined by TCID50. (C) Levels of positive sense viral RNA determined were
determined by RT qPCR. (D) VPg linked MNV-1 RNA was transfected in
293T cells overexpressing GFP-Hsp90 and the virus titer was determined 24 h
later using the TCID50. Each experiment was performed in triplicate, and the
error bars represent standard deviations. Statistical analysis was performed
using by one-way analysis of variance (ANOVA)with Bonferroni’s post test (*,
P
 0.05; ***, P
 0.001).
FIG 3 Hsp90 activity is required for MNV-1 replication. The requirement of
Hsp90 activity for MNV-1 replication was assessed by using Hsp90 activity
inhibitor and overexpression. (A) BV-2 cells were infected with MNV-1 at a
low MOI (0.01 TCID50/cell) and treated with 17-DMAG. Samples were har-
vested 24 h postinfection, and virus titers were determined by a TCID50 assay.
(B) Novobiocin, a small molecule that interacts with C-terminal ATP binding
site of Hsp90 to inhibit its activity, was used to confirm Hsp90-mediated in-
hibition of MNV-1. BV-2 cells were infected with MNV-1, and the medium
was supplemented with novobiocin. At 12 h postinfection, samples were har-
vested to determine virus titers by a TCID50 assay. (C) The cytotoxicity of
17-DMAG on BV-2 cells was determined by using a CellTiter-Blue assay, and
the inhibitory effect of 17-DMAG on MNV-1 replication was determined us-
ing the TCID50 during a high-MOI (5.0 TCID50/cell) infection. A concentra-
tion-effect curvewas plotted. The 50% cytotoxic concentration (CC50) and the
50% inhibitory concentration (IC50) were calculated from the curve after non-
linear regression analysis. The concentration of 17-DMAGused during further
studies is indicated as a dotted line. Each experiment was performed in tripli-
cate, and the error bars represent standard deviations. Statistical analysis was
performed using two-way ANOVA with Bonferroni’s post test (***, P 

0.001).
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peared to be equally affected; for example, the levels of NS6 and
NS7 were less affected thanNS1-2. These data, combined with the
observation that inhibition of Hsp90 activity has a greater impact
on viral infectivity than any observed effect on RNA synthesis,
suggested thatHsp90 activity contributes directly to the formation
of an infectious viral particle by regulating the stability of the
structural proteins.
The major capsid protein VP1 is a client protein of Hsp90.
Given the observation that inhibition of Hsp90 activity resulted in
the almost complete loss of several viral proteins, we sought to
determine whether any of the viral proteins were Hsp90 client
proteins and interacted directly with Hsp90. The Lumier quanti-
tative immunoprecipitation assay (55) was used to examine po-
tential interaction between Hsp90 and the various proteins en-
coded by MNV-1. Lumier was selected due to the ability to detect
low-affinity, transient interactions, often seen betweenHsp90 and
client proteins. Bait protein were fused to protein A and prey
proteins fused to Renilla luciferase. After expression in cells, bait
proteins were purified from cells using IgG bound to magnetic
beads, along with any associated luciferase-tagged prey proteins.
The normalized Lumier intensity ratios (NLIR) and rz score for
these NLIR values for each interaction pair was calculated as de-
scribed in Materials and Methods. The rz scores for each interac-
tion, a measure of the statistical significance of each interaction
(56), confirmed that interaction of Hsp90with NS1-2, NS3, and
VP1 was statistically significant (rz score  3.72  P 
 0.0001)
(Fig. 6A).
Based on the combination of data obtained to this point, we
reasoned that the antiviral activity of Hsp90 inhibitors was pri-
marily mediated by an effect on the viral capsid protein VP1.
Therefore, to further confirm VP1 as a Hsp90 client protein, the
effect of inhibiting Hsp90 activity on the stability of VP1 was then
examined outside the context of viral infection. The MNV-1
structural protein VP1 was overexpressed in cells either alone or
with VP2 from the MNV-1 subgenomic RNA. Samples treated
with 17-DMAG showed a reduced level of VP1, whether expressed
alone or with VP2 (Fig. 6B), whereas the level of NS7 remained
unaltered. Akt-1 is a well-known client protein of Hsp90 and was
used as positive control to confirm the effective inhibition of
Hsp90 activity (57). Taken together, these data independently
corroborated that the MNV-1 structural protein VP1 interacts
with Hsp90 and that its levels are reduced by inhibition of Hsp90
activity, confirming that VP1 is an Hsp90 client protein.
After inhibition of Hsp90, theMNV-1 VP1 protein is not de-
graded by a proteasomal or autophagy pathway. When Hsp90
activity is inhibited, client proteins are typically degraded via one
of the several host cell quality control mechanisms (58–60). Inhi-
FIG 4 17-DMAG affects MNV-1 replication after viral entry. 17-DMAG was
tested for its ability to inhibit MNV-1 infection at various time points postin-
fection. (A) To confirm that treatment with 17-DMAGdoes not affectMNV-1
virion stability and its infectivity, MNV-1 stock was treated for 1 h with 17-
DMAG, diluted, and titrated by using a TCID50 assay. (B) VPg-linkedMNV-1
RNA isolated from infected cells was transfected in 293T cells. After 4 h, the
cells were washed and supplemented with 17-DMAG or phosphate-buffered
saline-containing media. Samples were harvested after 24 h and virus titers
were plotted as determined by the TCID50. (C) BV-2 cells were infected with
MNV-1 at anMOI of 5 TCID50/cell, and 17-DMAGwas added at various times
postinfection. 17-DMAG significantly inhibits MNV-1 replication up to 9 h
postinfection. (D)The effect of 17-DMAGon the levels of host proteins known
to play a role inMNV-1 infectionwas determined by usingWestern blotting at
12 h postinfection. Each experiment was performed in triplicate, and the error
bars represent standard deviations. Statistical analysis was performed by two-
way ANOVA with Bonferroni’s post test (ns, nonsignificant; *, P
 0.05; ***,
P
 0.001).
FIG 5 Inhibition of Hsp90 activity leads to the inability of MNV-1 genome to
be encapsidated. A one-step growth curve ofMNV-1was carried out to analyze
the effect of 17-DMAG on virus titer (A) and genome copy number (B). (C)
The effect of 17-DMAGon the levels of viral proteins was determined by using
Western blotting at 12 h postinfection. Each experiment was performed in
triplicate, and the error bars represent the standard deviations. Statistical anal-
ysis was performed using by two-wayANOVAwith Bonferroni’s post test (***,
P
 0.001).
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bition of the degradative pathway involved in the loss of VP1 after
Hsp90 inhibition should therefore result in the restoration of the
VP1 protein levels. We thus examined the effect of inhibition of
the major cellular degradation pathways, namely, the proteasome
or autophagic pathways, in order to determine whether either of
these processes played a role in degradation of the MNV-1 VP1
protein upon Hsp90 inhibition. Lactacystin, a well-characterized,
specific proteasome inhibitor, was used to examine the role of the
proteasome in the degradation of MNV-1 structural protein VP1
after inhibition of Hsp90 activity. Treatment with lactacystin
failed to rescue 17-DMAGmediated reduction in the levels of VP1
protein in MNV-1-infected BV-2 cells (Fig. 7A). The accumula-
tion of p21, a cellular protein continuously degraded by protea-
some, was used as indicator of proteasome activity inhibition.We
also investigated whether autophagy was involved in 17-DMAG-
mediated reduction in the levels of VP1 using Atg5 knockout
BMDMs. MNV-1 replicated to similar titers in both Atg5-defi-
cient (Atg5flox/floxLysMcre) and wild-type (Atg5flox/flox) BMDMs
(34). Inhibition of Hsp90 activity using 17-DMAG reduced virus
titers significantly in both Atg5-deficient and wild-type BMDMs
(Fig. 7B). Similarly, the levels of viral protein VP1 were not res-
cued in Atg5-deficient BMDMs (Fig. 7C). These results indicated
that Hsp90 inhibition-mediated degradation of MNV-1 protein
VP1 is notmediated via either proteasome or autophagy. Further-
more, VP1 protein translation occurred in the presence of 17-
DMAG (data not shown), suggesting MNV-1 VP1 is most likely
degraded by a nonproteasomal and nonautophagy pathway.
However, identification of the degradation pathway for VP1 re-
quires further investigations.
Hsp90 activity is required for theMNV-1 replication in vivo.
To determine whether pharmacological inhibition of Hsp90 by
17-DMAG can impact norovirus replication in vivo, we used a
mouse model of acute MNV-1 infection. Light-sensitive, neutral
FIG 6 Hsp90 interacts with MNV-1 capsid protein and inhibition of Hsp90
activity leads to its degradation. (A) Lumier assay was used to detect direct
interaction of Hsp90 withMNV-1 proteins in 293T cells.MNV-1 proteins and
murine hsp90were expressed in fusion with either protein A (bait) orRenilla
luciferase (prey). The expressed proteins were pulled down using IgG, and the
interacting fusion Renilla luciferase activity was measured. The assay was per-
formed using Hsp90 as both prey and bait. The robust z scores were calculated
to measure the significance of interaction. The experiment was performed in
triplicate, and the error bars represent the standard deviations. (B) MNV-1
nonstructural (NS7) and structural (VP1) proteins were expressed in BSR-T7
cells and tested for the ability to be degraded in the presence of 17-DMAG. An
Hsp90 client protein, Akt, and GAPDH were used as positive and loading
controls, respectively. NS7 levels remained similar, whereas VP1 levels were
reduced in the presence of 17-DMAG.
FIG 7 Autophagy or proteasome activity is not involved in VP1 degradation.
(A) The effect of specific inhibitor of proteasome activity, lactacystin, on the
downregulation of MNV-1 protein levels due to 17-DMAG was examined
using Western blot analysis. P21, a cellular protein degraded by the protea-
some, was used as a positive control to confirm lactacystin activity in BV-2
cells. Akt-1, an Hsp90 client protein that is degraded by proteasome activity,
was used as a positive control to confirm the rescue the effect by inhibition of
proteasome activity. (B) Atg5-deficient (Atg5flox/floxLysMcre) BMDMs were
used to examine the role of autophagy in the degradation of MNV-1 capsid
protein. Atg5-deficient and control (Atg5flox/flox) BMDMs were infected with
MNV-1 at anMOI of 5 and treated with 17-DMAG. Samples were harvested at
24 h postinfection for virus titer and protein level determinations. The virus
titer was determined by using the TCID50. The experiment was performed in
triplicate, and the error bars represent the standard deviations. (C) The levels
of MNV-1 capsid protein VP1 and the autophagy markers, LC3-I and LC3-II,
were determined byWestern blot analysis. The conversion of LC3-I to LC3-II
is blocked in Atg5-deficient BMDMs, but the levels of VP1 are not rescued.
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red-containing virus was used as the inoculum to enable newly
replicated virus to be distinguished from input virus (35). Neutral
red is a photoactivatable small molecule that can be passively in-
corporated into virus particles during replication in cell culture.
Neutral red-containing virus becomes light sensitive as exposure
to light causes cross-linking between the viral RNA genome and
the protein coat (42). 17-DMAG was administered to BALB/c
mice intraperitoneally as a single bolus prior to infection, and the
effect on virus replication in the intestinewas examined. The effect
ofHsp90 activity inhibition on viral replication in the distal ileum,
the primary site of MNV-1 replication in vivo, was determined
(35, 42). Mice treated with 17-DMAG showed a significant de-
crease in virus titers compared to vehicle control-treated mice
(Fig. 8). These data confirmed a requirement of Hsp90 activity in
norovirus replication in vivo.
The HuNoV major capsid protein VP1 is a client protein of
Hsp90.To determinewhether our observations withMNV-1 held
true for the HuNoV, we examined whether any of the proteins
encoded by the prototype HuNoV, Norwalk virus, also interacted
with human Hsp90 using the Lumier assay. The rz scores for
each interaction confirmed that interaction of Hsp90 with
NS1-2, NS3, andVP1was statistically significant at a P of
0.0001
(data not shown) (Fig. 9A). To confirm that the Norwalk virus
VP1 protein was an Hsp90 client protein, we examined the effect
FIG 8 17-DMAG reduces acute MNV-1 infection in vivo. MNV-1 replica-
tion in mice is inhibited by 17-DMAG treatment. Three groups of five mice
each were either treated with 17-DMAG or vehicle in which 17-DMAG was
dissolved (0.05% DMSO) and then infected with MNV-1 labeled with neu-
tral red dye. After 24 h, the distal ilea were harvested, and the infectious
virus was titrated by a plaque assay either in dark (total) or in light (repli-
cated). Actively replicating, as well as total, MNV-1 titers were significantly
reduced. Statistical analysis was performed by using a Student t test (ns,
nonsignificant; **, P 
 0.01; ***, P 
 0.001). Error bars represent the
standard deviations.
FIG 9 Hsp90 interacts with HuNoV capsid protein, and inhibition of Hsp90 activity leads to its degradation. (A) A Lumier assay was used to detect direct
interaction of Hsp90 with HuNoV proteins in 293T cells, as stated in Fig. 6. HuNoV proteins and human hsp90 were expressed in fusion with either
protein A (bait) or Renilla luciferase (prey). The expressed proteins were pulled down using IgG, and the interacting fusion Renilla luciferase activity was
measured. The robust z scores were calculated to measure the significance of interaction. The assay was performed in both directions. The experiment was
performed in triplicate, and the error bars represent the standard deviations. (B) HuNoV structural protein VP1 was expressed in BSR-T7 cells and tested for the
ability to degrade in the presence of 17-DMAG. An Hsp90 client protein, Akt, and GAPDH were used as positive and loading controls, respectively.
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of inhibiting Hsp90 activity on VP1 levels when overexpressed in
cells. Cells were transfected with a plasmid containing the Nor-
walk virus subgenomic RNA, encoding both VP1 and VP2, and
the effect of 17-DMAG on VP1 levels was examined. As expected,
inhibition of Hsp90 activity caused a significant reduction in the
levels of the Norwalk virus VP1 protein (Fig. 9B). Taken together,
these data independently corroborated that theHuNoV structural
protein VP1 is also an Hsp90 client protein.
DISCUSSION
In our previous report, we had identified Hsp90 as a host factor
interacting with the termini of theMNV viral genomic RNA (32).
In the present study, we showed thatHsp90 is a potential target for
therapeutic intervention against noroviruses. Using Hsp90 inhib-
itors, we demonstrated that themajor role of Hsp90 activity in the
norovirus life cycle is during genome encapsidation. We con-
firmed that the MNV capsid protein VP1 is a client protein of
Hsp90 and that inhibition of Hsp90 activity causes VP1 degrada-
tion, most likely due to an inability to fold correctly. VP1 degra-
dation results in an inability of MNV-1 genomes to be encapsi-
dated and a significant reduction in the production of infectious
virions. We have further shown that HuNoV capsid protein VP1
also interacts with Hsp90 and that inhibition of Hsp90 activity
leads to the degradation of HuNoV VP1. Furthermore, we have
confirmed Hsp90 activity is required for norovirus replication in
vivo. Therefore, we propose that Hsp90may provide a viable ther-
apeutic target for the control of norovirus infections.
Noroviruses are the leading cause of viral gastroenteritis
throughout the world (1, 3), and outbreaks are common in semi-
closed facilities, including cruise ships, restaurants, schools, hos-
pitals, and caring homes (61, 62). Several factors, including high
infectivity of norovirus particles, the persistence of noroviruses in
the environment, a lack of lasting immunity, and prolonged shed-
ding of virus from infected individuals, contribute to the explosive
nature of norovirus outbreaks (63, 64). HuNoV infection usually
presents as an acute and self-limiting disease; however, norovirus
infection in infants and young children can develop into more
severe gastroenteritis, with symptoms lasting up to 6weeks (3, 65).
Although many vaccine candidates have undergone clinical trials
against noroviruses (66–72), the extreme genetic heterogeneity
within the virus family, a lack of intergenogroup cross-protection,
and rapidly emerging variant strainsmake generating a cross-pro-
tective vaccine a challenging, although not impossible, task. Vac-
cination is also not a suitable prevention strategy for immuno-
compromised and immunosuppressed patients, who often suffer
from long-term norovirus infections lasting months to years.
Therefore, the development of antiviral strategies for such patient
cohorts is of great interest. Several efforts have been made to de-
velop antiviral drugs against noroviruses (63, 73–78). Inhibitors
targeting the viral genome or proteins have been tested in both cell
culture and mouse models for their ability to inhibit norovirus
replication (73–77). Small molecule inhibitors of cellular path-
ways have also been shown to inhibitMNV replication in vitro and
in vivo; hippuristanol, a small molecule inhibitor of eIF4A, has
been shown to inhibitMNVRNA translation and virus replication
in cell culture (27), whereas a small molecule inhibitor of deubiq-
uitinases can also inhibit MNV replication in vivo (78). Despite
these efforts, no antiviral therapies are available to treat norovirus
infections.
At present, the majority of antiviral strategies target a single
viral protein. As a consequence, these antiviral drugs often have a
limited range of activity, often targeting only a single virus. The
high mutation rates of RNA virus genomes also make many anti-
viral drugs vulnerable to the rapid emergence of drug resistance.
In contrast, strategies designed to target host factors required for
viral replication not only have the potential to act on awider range
of viruses due to common mechanisms of replication but also
have a higher barrier to the development of resistance. This cellu-
lar targeting approach is gaining more enthusiasm and several
such host factors, required by many viruses, have now been
screened for inhibitors that may have broad-spectrum antiviral
activity (27, 78–81).
Our identification Hsp90 using a riboproteomics screen to
identify host factors that interact directly or indirectly with the 5=
and 3= termini of the MNV-1 genome (32) added to the growing
list of pathogens that utilize Hsp90 for some aspect of their life
cycle. Hsp90 is a highly abundant and evolutionarily conserved
molecular chaperone required for the conformationalmaturation
of numerous client proteins, enabling them to carry out their bi-
ological functions (33, 82, 83). In addition, Hsp90 is required for
the function of a large number of multiprotein complexes (84–
86). Hsp90 plays an important role in the replication of a broad
range of both DNA and RNA viruses (33). For example, in hepa-
titis C virus Hsp90 is essential for NS2/3 protease activity and
stabilizes the NS3 protein (87, 88), and in human immunodefi-
ciency virus type 1 Hsp90 controls reactivation from latency (89),
whereas in poliovirus Hsp90 is required for maturation and pro-
cessing of the capsid protein precursor (P1) (49). Nonstructural
proteins of MNV are encoded in a single open reading frame.
However, the levels of some nonstructural proteins were affected
more than others (e.g., compare levels of NS1/2 and NS3 in Fig.
5C). However, given a minor effect on viral RNA levels, but a
major effect on infectious virus production, we focused our stud-
ies on the structural proteinVP1.Our data, presented in Fig. 6 and
9, indicate that the structural protein VP1 of MNV and HuNoV
are client proteins of Hsp90. The specific sequence requirements
for the interaction of Hsp90 with theMNV-1 RNA are beyond the
scope of the present study and will require further investigations;
however, they fit with previous observations of RNA binding ac-
tivity observed with bamboo mosaic virus (46). Hsp90 has previ-
ously been shown to interact with the genomic RNA of bamboo
mosaic virus (46). The interaction ofHsp90with a structural RNA
motif in the 3=UTR of the bamboo mosaic virus genomic RNA
conferred its requirement for bamboo mosaic virus but not for
bamboo mosaic virus-associated satellite virus. The role of the
observed RNA binding activity in the norovirus life cycle also re-
mains to be determined. It is possible that an interactionwith viral
RNA functions to recruit Hsp90 to newly synthesized viral RNA
where it may then recruit VP1 subunits to initiate genome encap-
sidation. Further studies are clearly required to delineate the pre-
cise role of the RNA binding activity.
The requirement ofHsp90 activity in numerous viral life cycles
is not surprising, given that viruses typically need to rapidly pro-
duce a large quantity of a limited number of structurally complex
proteins. For example, a viral structural proteinmust adopt a pre-
cursor conformation that is soluble, but hundreds to thousands of
such protein units must then be orderly assembled into a capsid
formation in the presence of viral genome that remains infectious
despite extreme thermal and chemical conditions (90). The re-
quirement of Hsp90 activity for pathways associated with cancer-
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ous cell proliferation has driven the development of inhibitors
targeting Hsp90 activity (47, 91). Themost effective inhibitors are
based on the ansamycin antibiotic GA, which prevents ATP bind-
ing to Hsp90, rendering it inactive. There has been enormous
interest in the development of Hsp90 inhibitors with an accept-
able safety profile for the treatment of several cancers (47), and
should any of these possess the correct toxicity profile, we would
suggest that there is a possibility to repurpose these Hsp90 inhib-
itors against noroviruses.
To summarize, we have shown that host chaperone Hsp90
plays an important role in the stability of the norovirus capsid
protein and that Hsp90 activity is required forMNV-1 replication
in vitro, as well as in in vivomousemodels.We extended this work
to demonstrate thatHsp90 activity is also required for theHuNoV
capsid protein stability, identifying Hsp90 as a common cellular
component contributing to the norovirus life cycle. Further work
is required to explore the utility of Hsp90 as a potential therapeu-
tic target against these clinically important pathogens.
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